Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Thyroid Neoplasms 1Skin Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

mogamulizumab 3Cyclophosphamide 3Lenalidomide 2Alemtuzumab 2ruxolitinib 1peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1denileukin diftitox 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia-Lymphoma, Adult T-Cell × Interleukin-15 × Clear all
NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡